血尿酸与系统性红斑狼疮患者肾损害的关系  

Association of serum uric acid with lupus nephritis in systemic lupus erythematosus patients

作　　者：陈宪[1] 周蕾[1] 庞杰[1] 李晓洁[1] 王颖嫒[1] 

机构地区：[1]天津医科大学总医院感染免疫科,天津300052

出　　处：《天津医科大学学报》2014年第1期42-44,共3页Journal of Tianjin Medical University

基　　金：天津市卫生局科技基金资助项目(09k2111)

摘　　要：目的：探讨血尿酸与系统性红斑狼疮（SI正）患者肾损害的关系。方法：SLE患者210例，根据是否伴发肾损害分为狼疮肾组（LN）和非狼疮肾组（NLN）。评估每例SLE患者的疾病活动指数（SLEDAI），并同时检测空腹血尿酸、补体C3、补体C4、C反应蛋白（CRP）等指标。统计学处理组间比较采用t检验；相关性分析采用Logistic回归分析；应用受试者工作特征（ROC）曲线，评价血尿酸对LN的预测价值。结果：LN组与NLN组患者相比血尿酸水平[（383．243±55．622）umol／L vs（246．257±92．283）umol/L]、SLEDAI[（11．970±5．275）vs（7．600±4．175）]升高（P〈0．01），补体C3[（491．62±245．30）mg／LVS（584．77±235．72）mg／L]降低，差异具有统计学意义。Logistic回归分析提示血尿酸水平升高和补体c3是I州的危险因素。以血尿酸水平绘制ROC曲线，曲线下面积是0．921（95％CI=O．870-0．972，P〈0．01）。结论：SLE合并肾损害患者血尿酸水平高于无肾损害患者，血尿酸水平升高是肾损害的危险因素。Objective： To investigate the association of elevated plasma uric acid （UA）with lupus nephritis （LN） in systemic lupus erythematosus （SLE） patients. Methods： A total of 210 patients with SLE were evaluated and divided into LN group and NEN group. Relevant clinical indicators of the two groups plasma UA, complement 3, complement 4 were analyzed by Students-t test. Logistic regression analysis was used to analyze the possible factors that might affect the LN. Receiver operating characteristics curves （ROC） method was applied to evaluate plasma UA predictive value of LN. Results： Plasma UA was higher in LN group than NLN group, and complement C3 were lower than the NLN group. Plasma UA , SLEDAI and complement C3 all increased [（383.243±55.622） umo]/L vs （246.257 ±92.283） umo]/L, （11.970±5.275） vs （7.600±4.175） and （491.62±245.30）mg/Lvs （584.77±235.72） mg/L respectively]. Logistic analysis showed that UA and complement C3 were independent risk factors of LN. The area under the ROC for plasma UA was 0.921 （95% CI=0.870-0.972, P〈0.01 ）. Conclusion： The SLE patients with renal damage are higher in plasma UA than without renal damage. The elevated plasma UA level is an independent risk factor for attack of LN.

关 键 词：红斑狼疮 系统性 尿酸 肾损害 

分 类 号：R593.241[医药卫生—内科学]